政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/54123

政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/54123

English | 正體中文 | 简体中文 | Post-Print筆數 : 27 | 全文筆數/總筆數 : 113392/144379 (79%)
造訪人次 : 51224942 線上人數 : 888

RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

搜尋範圍

查詢小技巧：

您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果

若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料

進階搜尋

主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於政大典藏 ‧ 管理

到手機版

政大機構典藏 > 理學院 > 應用數學系 > 學位論文 > Item 140.119/54123

請使用永久網址來引用或連結此文件: https://nccur.lib.nccu.edu.tw/handle/140.119/54123

題名:	在特定癌症模型上的最佳治療策略 Optimal policies of non-cross-resistant chemotherapy on a cancer model
作者:	郭雅慧
貢獻者:	陳政輝郭雅慧
關鍵詞:	數學模型抗藥性突變最佳治療 mathematical model drug resistance mutation optimal therapy
日期:	2011
上傳時間:	2012-10-24 16:37:37 (UTC+8)
摘要:	數學模型可被用於癌症之化療研究。一個著名的例子為學者Goldie和Coldman在1979年發表了第一個描述癌症化療中，腫瘤細胞突變率及其與治療藥物反應關聯性之數學模型。此一模型因對此問題之描述簡潔與優雅，廣為其他學者引用。Goldie和Coldman(經與Guaduskas合作)隨後於1982年利用此模型配合模擬方法說明在沒有交互抗藥性的治療中，就避免腫瘤細胞發生多重抗藥性突變而言，為何交替使用治療藥物為最佳治療方式。其後更在1983年，於考慮隨機特性下，推廣原有模型，並考慮此推廣模型之近似表示時，以嚴格數學方法證明其於1982年以模擬方法所得之結論。然而，Goldie和Coldman之理論分析工作多集中於模型參數具有對稱結構之情形，而關於模型參數不具對稱結構時，文獻中少有理論分析之探討。於此一論文中，我們重新以多階段最佳化問題表達此一問題，並考慮模型參數不完全對稱下，最佳治療方式所應滿足之條件。根據我們提出的架構，可求得不完全對稱下最佳治療方式之解析解。此外，Goldie和Coldman關於模型參數具對稱結構之工作可視為我們架構下之一特例。因此，我們的架構提供Goldie和Coldman理論分析工作一個新的數學證明方法。本文除理論推導外，並以數值方法進行案例分析，以驗證我們工作之正確性。 Mathematical models can be applied to study the chemotherapies on tumor cells. Espeically, in 1979, Goldie and Coldman proposed the first mathematical model to relate the drug sensitivity of tumors to their mutation rates. This pioneering work is subsequently referred by many scientists due to its simplicity and elegancy. The authors (jointly with Guaduskas) later used their model to explain why alternating non-crossresistant chemotherapy is optimal with simulation approach. Subsequently in 1983, they proposed an extended stochastic based model and provided a rigorous mathematical proof to their earlier simulation work when the extended model is approximated by its quasi-approximation. However, Goldie and Coldman’s analytic work on optimal treatments majorly focuses on process with symmetrical parameter settings. Little theoretical results on asymmetrical settings are discussed. In this thesis, we recast and restate Goldie, Coldman and Guaduskas’ model as a multi-stage optimization problem. Under an asymmetrical assumption, conditions under which a treatment policy can be optimal are derived. This framework enables us to consider some optimal policies on the model analytically. In addition, Goldie, Coldman and Guaduskas’ work with symmetrical settings can be treated as a special case of our framework. Base on the derived conditions, an alternative proof to Goldie and Coldman’s work is provided. In addition to the theoretical derivation, numerical results are included to justify the correctness of our work. 1 Introduction ............................................ 1 2 The Model Framework ..................................... 3 2.1 The Treatment Phase ................................... 3 2.2 The Growth Phase ...................................... 5 2.3 Probability of Occurrence of No Double Resistance ..... 7 3 The Optimal n-Cycle Treatment Problem .................. 10 3.1 Treatment Phase at the ith Cycle ..................... 12 3.2 Growth Phase at the ith Cycle ........................ 13 3.3 Optimal n-Cycle Treatment Problem .................... 13 4 Optimal Therapy under Equal Efficacy Assumptions ....... 15 5 Optimal Therapy under Equal Mutation Rates ............. 21 5.1 The Mutation Rates alpha1=alpha2=alpha1,2=alpha2,1 ... 21 5.2 The Mutation Rates alpha1=alpha2 and alpha1,2=alpha2,1 26 6 Optimal Therapy under Unequal Mutation Rates ........... 31 7 Discussions ............................................ 37 References ............................................... 39 Appendix A ............................................... 42 Appendix B ............................................... 47 Appendix C ............................................... 50 Appendix D ............................................... 51 Appendix E ............................................... 53 Appendix F ............................................... 56
參考文獻:	[1] L. Cojocaru and Z. Agur, “A theoretical analysis of interval drug dosing for cell-cycle-phase-specific drugs,” Math. Biosci., vol. 109, no. 1, pp. 85-97, 1992. [2] A. J. Coldman and J. H. Goldie, “A model for the resistance of tumor cells to cancer chemotherapeutic agents,” Math. Biosci., vol. 65, pp. 291-307, 1983. [3] R. Day, “Treatment sequencing, asymmetry and uncertainty: new strategies for combining cancer tretatments,” Cancer Res., vol. 46, pp. 3876-3885, 1986. [4] J. H. Goldie and A. J. Coldman, “A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate,” Cancer Treatment Reports, vol. 63, no. 11-12, pp. 1727-1733, 1979. [5] J. H. Goldie, A. J. Coldman and G. A. Gudauskas, “Rationale for the use of alternating non-cross-resistant chemotherapy,” Cancer Treatment Reports, vol.66, no. 3, pp. 439-449, 1982. [6] J. H. Goldie and A. J. Coldman, Drug Resistance in Cancer: Mechanisms and Models, Cambridge, 1998. [7] E. A. Gaffney, “The application of mathematical modelling to aspects of adjuvant chemotherapy scheduling,” J. Math. Biol., vol. 48, no. 4, pp. 375-422, 2004. [8] E. A. Gaffney, “The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics,”Bull. Math. Biol., vol. 67, no. 3, pp. 563-611, 2005. [9] S. N. Gardner and M. Fernandes, “New tools for cancer chemotherapy computational assistance for tailoring treatments,” Mol. Cancer Ther., vol. 2, no. 10, pp. 1079-1084, 2003. [10] L. E. Harnevo and Z. Agur, “The dynamics of gene amplification described as a multitype compartmental model and as a branching process,” Math. Biosci., vol. 103, no. 1, pp. 115-138, 1991. [11] L. E. Harnevo and Z. Agur, “Use of mathematical models for understanding the dynamics of gene amplification,” Mutat. Res., vol. 292, no. 1, pp. 17-24, 1993. [12] Y. Iwasa, F. Michor and M. A. Nowak, “Stochastic tunnels in evolutionary dynamics,” Genetics, vol. 166, no. 3, pp. 1571-1579, 2004. [13] T. L. Jackson and H. M. Byrne, “A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy,”Math. Biosci., vol. 164, no. 1, pp. 17-38, 2000. [14] M. Kimmel and D. E. Axelrod, “Mathematical models of gene amplification with applications to cellular drug resistance and tumorigenicity,” Genetics, vol. 125, no. 3, pp. 633-644, 1990. [15] M. Kimmel and D. N. Stivers, “Time-continuous branching walk models of unstable gene amplification,” Bull. Math. Biol., vol. 56, no. 2, pp. 337-357, 1994. [16] M. Kimmel, A. Swierniak and A. Polanski, “Infinite-dimensional model of evolution of drug resistance of cancer cells,” J. Math. Syst. Est. Control, vol. 8, pp. 1-16, 1998. [17] N. Komarova, “Stochastic modeling of durg resistance in cancer,” Journal of Theoretical Biology, vol. 239, pp. 351-366, 2006. [18] J. M. Murry and A. J. Coldman, “The effect of heterogeneity on optimal regimens in cancer chemotherapy,” Math. Bioscie., vol. 185, no. 1, pp. 73-87, 2003. [19] R. M. Ross, Stochastic Processes, Wiley, 1983. 20] H. S. Skipper, F. M. Schabel and W. S. Wilcox, “Experimental evaluation of potential anti-cancer agent. XIV Further study of certain basic concepts underlying the chemotherapy of leukemia,” Cancer Chemother. Rep., vol. 45, pp. 5-28, 1975. [21] A. Swierniak and J. Smieja, “Cancer chemotherapy optimization under evolving drug resistance,” Nonlindear Anal., vol. 47, pp. 375-386, 2001.
描述:	碩士國立政治大學應用數學研究所 97751013 100
資料來源:	http://thesis.lib.nccu.edu.tw/record/#G0977510131
資料類型:	thesis
顯示於類別:	[應用數學系] 學位論文

文件中的檔案:

檔案	大小	格式	瀏覽次數
index.html	0Kb	HTML2	367	檢視/開啟

在政大典藏中所有的資料項目都受到原著作權保護.

社群 sharing

著作權政策宣告 Copyright Announcement

1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.

DSpace Software Copyright © 2002-2004 MIT & Hewlett-Packard / Enhanced by NTU Library IR team Copyright © - 回饋